Miller Anestesia

60. Baker MT, Ronnenberg WC Jr, Ruzicka JA, et al:

Inhibitory effects of deuterium substitution on the

metabolism of sevoflurane by the rat. Drug Metab

Dispos 21:1170–1171, 1993.

61. Hoffman J, Konopka K, Buckhorn C, et al: Ethanol-

inducible cytochrome P450 in rabbits metabolizes

enflurane. Br J Anaesth 63:103–108, 1989.

62. Kikuchi H, Morio M, Fuijii K, et al: Clinical evalua-

tion and metabolism of sevoflurane in patients.

Hiroshima J Med Sci 36:93–97, 1987.

63. Frink EJ Jr, Ghantous H, Malan TP, et al: Plasma

inorganic fluoride with sevoflurane anesthesia:

Correlation with indices of hepatic and renal

function. Anesth Analg 74:231–235, 1992.

64. Drayer DE: Pharmacodynamic and pharmacokine-

tic differences between drug enantiomers in

humans: An overview. Clin Pharmacol Ther

40:125–133, 1986.

65. Tucker GT, Lennard MS: Enantiomer specific phar-

macokinetics. Pharmacol Ther 45:309–329, 1990.

66. Birkett DJ: Racemates or enantiomers: Regulatory

approaches. Clin Exp Pharmacol Physiol 16:479–

483, 1989.

67. Ariens EJ, Testa B: Chiral aspects of drug metabo-

lism. Trends Pharmacol Sci 7:60–64, 1986.

68. Howard-Lock HE, Lock CJ, Mewa A, Kean WF:

-Penicillamine: Chemistry and clinical use in

rheumatic disease. Semin Arthritis Rheum 15:261–

281, 1986.

69. Satoh K,Yanagisawa T,Taira N: Coronary vasodilator

and cardiac effects of optical isomers of verapamil in

the dog. J Cardiovasc Pharmacol 2:309–318, 1980.

70. Powell JR, Ambre JJ, Rud TI: Drug stereochemistry.

Wainer IW, Drayer DE (eds): Analytical Methods

and Pharmacology. New York, Dekker, 1988, p 245.

71. Buchinger W, Ober O, Uray G, et al: Synthesis and

effects on peripheral thyroid hormone conversion

of (

)-4-hydroxypropanolol, a main metabolite of

(

)-propranolol. Chirality 3:145, 1991.

72. Grisslinger G, Hering W, Thomann P, et al: Pharma-

cokinetics and pharmacodynamics of ketamine

enantiomers in surgical patients using a stereoselec-

tive analytical method. Br J Anaesth 70:666–671,

1993.

73. Kharasch ED, Labroo R: Metabolism of ketamine

stereoisomers by human liver microsomes. Anes-

thesiology 77:1201–1207, 1992.

74. Brau ME, Branitzki P, Olschewski A, et al: Block of

neuronal tetrodotoxin-resistant Na currents by ste-

reoisomers of piperidine local anesthetics. Anesth

Analg 91:1499–1505, 2000.

75. Heavner JE: Local anesthetics. Curr Opin Anaesthe-

siol 20:336–342, 2007.

76. Thomas JM, Schug SA: Recent advances in the phar-

macokinetics of local anaesthetics. Long-acting

amide enantiomers and continuous infusions. Clin

Pharmacokinet 36:67–83, 1999.

77. Blaschke G, Kraft HP, Fickentscher K, Kohler F:

Chromatographic separation of racemic thalido-

mide and teratogenic activity of its enantiomers

(author’s transl). Arzneimittelforschung 29:1640–

1642, 1979.

78. Martin JL, Meinwald J, Radford P, et al: Stereoselec-

tive metabolism of halothane enantiomers to tri-

fluoroacetylated liver proteins. Drug Metab Rev

27:179–189, 1995.

79. Kendig JJ, Trudell JR, Cohen EN: Halothane stere-

oisomers: Lack of stereospecificity in two model

systems. Anesthesiology 39:518–524, 1973.

80. Lysko GS, Robinson JL, Castro R, Ferrone RA: The

stereospecific effects of isoflurane isomers in vivo.

Eur J Pharmacol 263:25–29, 1994.

81. Harris B,Moody E,Skolnick P: Isoflurane anesthesia is

stereoselective. Eur J Pharmacol 217:215–216, 1992.

82. Moody EJ, Harris BD, Skolnick P: Stereospecific

actions of the inhalation anesthetic isoflurane at the

GABA

receptor complex. Brain Res 615:101–106,

1993.

83. Jones MV, Harrison NL: Effects of volatile anesthe-

tics on the kinetics of inhibitory postsynaptic

currents in cultured rat hippocampal neurons.

J Neurophysiol 70:1339–1349, 1993.

84. Harris BD, Moody EJ, Basile AS, Skolnick P: Volatile

anesthetics bidirectionally and stereospecifically

modulate ligand binding to GABA receptors. Eur

J Pharmacol 267:269–274, 1994.

85. Tomlin SL, Jenkins A, Lieb WR, Franks NP: Stereo-

selective effects of etomidate optical isomers on

gamma-aminobutyric acid type A receptors and

animals. Anesthesiology 88:708–717, 1998.

86. Summary of the national Halothane Study: Possible

association between halothane anesthesia and

postoperative hepatic necrosis. JAMA 197:775–788,

1966.

87. Martin JL, Plevak DJ, Flannery KD, et al: Hepato-

toxicity after desflurane anesthesia. Anesthesiology

83:1125–1129, 1995.

88. Uetrecht J: Idiosyncratic drug reactions: Past,present,

and future. Chem Res Toxicol 21:84–92, 2008.

89. Park BK, Kitteringham NR, Maggs JL, et al: The role

of metabolic activation in drug-induced hepatotoxi-

city. Annu Rev Pharmacol Toxicol 45:177–202,

2005.

90. Pohl LR, Pumford NR, Martin JL: Mechanisms,

chemical structures and drug metabolism. Eur J

Haematol Suppl 60:98–104, 1996.

91. Kenna JG: Immunoallergic drug-induced hepatitis:

Lessons from halothane. J Hepatol 26(Suppl 1):5–

12, 1997.

92. Kenna JG, Satoh H, Christ DD, Pohl LR: Metabolic

basis for a drug hypersensitivity: Antibodies in sera

from patients with halothane hepatitis recognize

liver neoantigens that contain the trifluoroacetyl

group derived from halothane. J Pharmacol Exp

Ther 245:1103–1109, 1988.

93. Martin JL, Pumfoprd NR, LaRosa AC, et al: A meta-

bolite of halothane covalently binds to an endoplas-

mic reticulum protein that is highly homologous to

phosphatidylinositol-specificphospholipaseC-alpha

but has no activity. Biochem Biophys Res Commun

178:679–685, 1991.

94. Butler LE, Thomassen D, Martin JL, et al: The cal-

cium-binding protein calreticulin is covalently

modified in rat liver by a reactive metabolite of the

inhalation anesthetic halothane. Chem Res Toxicol

5:406–410, 1992.

95. Martin JL, Reed GF, Pohl LR: Association of anti–58

kDa endoplasmic reticulum antibodies with halo-

thane hepatitis. Biochem Pharmacol 46:1247–1250,

1993.

96. Martin JL, Kenna JG, Martin BM, et al: Halothane

hepatitis patients have serum antibodies that react

with protein disulfide isomerase. Hepatology

18:858–863, 1993.

97. Pumford NR, Martin BM, Thomassen D, et al:

Serum antibodies from halothane hepatitis patients

react with the rat endoplasmic reticulum protein

ERp72. Chem Res Toxicol 6:609–615, 1993.

98. Bourdi M, Demady D, Martin JL, et al: cDNA

cloning and baculovirus expression of the human

liver endoplasmic reticulum P58: Characterization

as a protein disulfide isomerase isoform, but not as

a protease or a carnitine acyltransferase. Arch

Biochem Biophys 323:397–403, 1995.

99. Pohl LR: An immunochemical approach of identi-

fying and characterizing protein targets of toxic

reactive metabolites. Chem Res Toxicol 6:786–793,

1993.

100. Gut J, Christen U, Huwyler J: Mechanisms of halo-

thane toxicity: Novel insights. Pharmacol Ther

58:133–155, 1993.

101. Barton J: Jaundice and halothane. Lancet 1:1097,

1959.

102. Wark HJ: Postoperative jaundice in children. The

influence of halothane. Anaesthesia 38:237–242,

1983.

103. Warner LO, Beach TP, Garvin JP, Warner EJ: Halo-

thane and children: The first quarter century.Anesth

Analg 63:838–840, 1984.

104. Kenna JG, Neuberger J, Mieli-Vergani G, et al: Halo-

thane hepatitis in children. Br Med J (Clin Res Ed)

294:1209–1211, 1987.

105. Njoku D, Laster MJ, Gong DH, et al: Biotransforma-

tion of halothane, enflurane, isoflurane, and desflu-

rane to trifluoroacetylated liver

proteins:Association

between protein acylation and hepatic injury.

Anesth Analg 84:173–178, 1997.

106. Christ DD, Kenna JG, Kammerer W, et al: Enflurane

metabolism produces covalently bound liver

adducts recognized by antibodies from patients

with halothane hepatitis. Anesthesiology 69:833–

838, 1988.

107. Brunt EM, White H, Marsh JW, et al: Fulminant

hepatic failure after repeated exposure to isoflurane

anesthesia: A case report. Hepatology 13:1017–

1021, 1991.

108. Turner GB, O’Rourke D, Scott GO, Beringer TR:

Fatal hepatotoxicity after re-exposure to isoflurane:

A case report and review of the literature. Eur J

Gastroenterol Hepatol 12:955–959, 2000.

109. Njoku DB, Shrestha S, Soloway R, et al: Subcellular

localization of trifluoroacetylated liver proteins in

association with hepatitis following isoflurane.

Anesthesiology 96:757–761, 2002.

110. Jones RM, Koblin DD, Cashman JN, et al: Biotrans-

formation and hepato-renal function in volunteers

after exposure to desflurane (I-653). Br J Anaesth

64:482–487, 1990.

111. Wrigley SR, Fairfield JE, Jones RM, Black AE:

Induction and recovery characteristics of desflurane

in day case patients: A comparison with propofol.

Anaesthesia 46:615–622, 1991.

112. Berghaus TM, Baron A, Geier A, et al: Hepatotoxi-

city following desflurane anesthesia. Hepatology

29:613–614, 1999.

113. Anderson JS, Rose NR, Martin JL, et al: Desflurane

hepatitis associated with hapten and autoantigen-

specific IgG4 antibodies. Anesth Analg 104:1452–

1453, 2007.

114. Cote G, Bouchard S: Hepatotoxicity after desflurane

anesthesia in a 15-month-old child with Möbius

syndrome after previous exposure to isoflurane.

Anesthesiology 107:843–845, 2007.

115. Watanabe K, Hatakenaka S, Ikemune K, et al:

[A case of suspected liver dysfunction induced

by sevoflurane anesthesia]. Masui 42:902–905,

1993.

116. Shichinohe Y, Masuda Y, Takahashi H, et al: [A case

of postoperative hepatic injury after sevoflurane

anesthesia]. Masui 41:1802–1805, 1992.

117. Bruun LS, ELKjaer S, Bitsch-Larsen D, Anderson O:

Hepatic failure in a child after acetaminophen and

sevoflurane exposure. Anesth Analg 92(6)1446–

1488, 2001.

118. Lehmann A, Neher M, Kiessling AH: Case report:

fatal hepatic failure after aortic valve replacement

and sevoflurane exposure.Can JAnaesth 54(11)917–

921, 2007.

119. Harris JW, Pohl LR, Martin JL, Anders MW: Tissue

acylation by the chlorofluorocarbon substitute

2,2-dichloro-1,1,1-trifluoroethane. Proc Natl Acad

Sci U S A 88(4)1407–1410, 1991.

120. Lind RC, Gandolfi AJ, Hall PD: Biotransformation

and hepatotoxicity of HCFC-123 in the guinea pig:

Potentiation of hepatic injury by prior glutathione

depletion. Toxicol Appl Pharmacol 134(1)175–181,

1995.

121. Rusch GM, Trochimonicz HJ, Malley LJ, et al: Sub-

chronic inhalation toxicity studies with hydrochlo-

rofluorocarbon 123 (HCFC 123). Fundam Appl

Toxicol 23(2)169–178, 1994.

122. Dekant W: Toxicology of chlorofluorocarbon repla-

cements. Environ Health Perspect 104(Suppl 1):75–

83, 1996.

Anestésicos inhalatorios: metabolismo y toxicidad

429

Sección II

Farmacología y anestesia